Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > BUSINESS
BUSINESS
- Sanofi-aventis Applies for Switch OTC Allegra, PAFSC Committee to Review on June 7
May 28, 2012
- 26 TSE 1st-Section Drug Makers Post Overall Decline in Sales, Profits for FY2011: JPMA
May 28, 2012
- Meiji Seika Pharma Aims to Increase No. of MRs to 900 as Soon as Possible
May 28, 2012
- Nearly 30% Use “Only Neostigmine”: Neuromuscular Antagonists Usage Survey
May 28, 2012
- US Subsidiary of DSP Settles COPD Drug Patent Infringement Suit
May 28, 2012
- DPP-4 Inhibitors Gain Traction, Boosting Diabetes Market by 15.5%: IMS Japan
May 25, 2012
- Zeria Projects 19% Increase in Asacol Sales to 12.2 Billion Yen in FY2012
May 25, 2012
- Japanese Ethical Drug Market Expands by 5.5% to 9.5348 Trillion Yen: IMS Japan
May 25, 2012
- Takeda Files MAA for Alogliptin in Europe
May 25, 2012
- National Cancer Center, Daiichi Sankyo Conclude Comprehensive Joint Research Agreement for Cancer Drug Discovery
May 24, 2012
- RIKEN and Takeda Open Collaboration Center for Developing Drug Discovery Technology for CNS Diseases
May 24, 2012
- Daiichi Sankyo Completes Patient Recruitment in Overseas PIII Trial of ARQ 197 for NSCLC
May 24, 2012
- Xarelto No. 1, Prazaxa Ranks 2nd in Call Frequency in HP Market: Rep Track April Survey
May 24, 2012
- Meiji HD Targets Pharmaceuticals Segment Sales at 140 Billion Yen in FY2014
May 23, 2012
- Four Major Listed Dispensing Pharmacies Post Record Performance in FY2011
May 23, 2012
- Myslee Is Most Prescribed Insomnia Drug: Survey
May 23, 2012
- AnGes MG to Allocate Shares Worth 200 Million Yen to Shionogi to Develop NF-κB Decoy Oligo
May 23, 2012
- 11 Leading Foreign-Affiliated Drug Makers Report 12% Growth in Sales in 2011 Driven by New Drugs
May 23, 2012
- NDA Filed for Anti-Androgen Drug MDV3100 in the US: Astellas
May 23, 2012
- Japan Vaccine to Make All-Out Effort,“Invest All Resources” in Cervical Cancer, Rotavirus Vaccines
May 22, 2012
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…